Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.

Sofroniadou S, Goldsmith D.

Drug Saf. 2011 Feb 1;34(2):97-115. doi: 10.2165/11585040-000000000-00000.

PMID:
21247219
2.

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Teachey DT, Grupp SA, Brown VI.

Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. Review.

3.

Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology.

Fogel AL, Hill S, Teng JM.

J Am Acad Dermatol. 2015 May;72(5):879-89. doi: 10.1016/j.jaad.2015.01.014. Epub 2015 Mar 11. Review.

PMID:
25769191
4.

Placental, lipid, and glucidic effects of mammalian target of rapamycin inhibitors: impact on fetal growth and metabolic disorders during pregnancy after solid organ transplantation.

Framarino-dei-Malatesta M, Derme M, Napoli A, Iaria G, Manzia TM, Orlando G, Casorelli A, Berloco P.

Transplant Proc. 2014 Sep;46(7):2254-8. doi: 10.1016/j.transproceed.2014.07.047. Review.

PMID:
25242764
5.

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.

Khokhar NZ, Altman JK, Platanias LC.

Curr Opin Oncol. 2011 Nov;23(6):578-86. doi: 10.1097/CCO.0b013e32834b892d. Review.

PMID:
21892085
6.

Adverse events associated with mTOR inhibitors.

Pallet N, Legendre C.

Expert Opin Drug Saf. 2013 Mar;12(2):177-86. doi: 10.1517/14740338.2013.752814. Epub 2012 Dec 20. Review.

PMID:
23252795
7.

mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.

Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J.

Int J Cancer. 2016 May 15;138(10):2312-21. doi: 10.1002/ijc.29887. Epub 2015 Oct 27. Review.

PMID:
26452336
8.

Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.

Xu J, Tian D.

Curr Med Res Opin. 2014 Jan;30(1):67-74. doi: 10.1185/03007995.2013.844116. Epub 2013 Oct 4. Review.

PMID:
24028709
9.

mTOR kinase inhibitors as a treatment strategy in hematological malignancies.

Grzybowska-Izydorczyk O, Smolewski P.

Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Review.

PMID:
22416776
10.

Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use.

Touzot M, Soulillou JP, Dantal J.

Curr Opin Organ Transplant. 2012 Dec;17(6):626-33. doi: 10.1097/MOT.0b013e32835a4be2. Review.

PMID:
23080066
11.

[Use of mTOR-inhibitors in solid tumors].

Seidel C, Gr├╝nwald V.

Med Monatsschr Pharm. 2011 Apr;34(4):116-26; quiz 127-8. Review. German.

PMID:
21528529
12.

[Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].

Caletti C, Granata S, Tomei P, Lupo A, Zaza G.

G Ital Nefrol. 2014 Jul-Aug;31(4). pii: gin/31.4.2. Review. Italian.

PMID:
25098457
13.

Mammalian target of rapamycin as a target in hematological malignancies.

Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS.

Target Oncol. 2011 Mar;6(1):53-61. doi: 10.1007/s11523-011-0175-8. Epub 2011 Apr 17. Review.

PMID:
21499765
14.

Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.

Kahan B.

Expert Opin Drug Saf. 2011 Sep;10(5):727-49. doi: 10.1517/14740338.2011.579898. Epub 2011 May 11. Review.

PMID:
21557712
15.

Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?

Bhat M, Watt KD.

Clin Transplant. 2015 Jul;29(7):654-63. doi: 10.1111/ctr.12559. Epub 2015 Jun 10. Review.

PMID:
26094583
16.

The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.

Klintmalm GB, Saab S, Hong JC, Nashan B.

Clin Transplant. 2014 Jun;28(6):635-48. doi: 10.1111/ctr.12357. Epub 2014 Apr 21. Review.

PMID:
24628264
17.

mTOR inhibitors and renal allograft: Yin and Yang.

Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A.

J Nephrol. 2014 Oct;27(5):495-506. doi: 10.1007/s40620-014-0103-y. Epub 2014 May 8. Review.

PMID:
24804854
18.

Strategies for the management of adverse events associated with mTOR inhibitors.

Kaplan B, Qazi Y, Wellen JR.

Transplant Rev (Orlando). 2014 Jul;28(3):126-33. doi: 10.1016/j.trre.2014.03.002. Epub 2014 Mar 12. Review.

19.

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.

Coiffier B, Ribrag V.

Leuk Lymphoma. 2009 Dec;50(12):1916-30. doi: 10.3109/10428190903207548. Review.

PMID:
19757306
20.

Sirolimus and everolimus in kidney transplantation.

Moes DJ, Guchelaar HJ, de Fijter JW.

Drug Discov Today. 2015 Oct;20(10):1243-9. doi: 10.1016/j.drudis.2015.05.006. Epub 2015 Jun 4. Review.

PMID:
26050578

Supplemental Content

Support Center